Our study differs from the research conducted by Manchanda et al31 on the cost-effectiveness of population-based testing for BRCA1, BRCA2, RAD51C (OMIM 602774), RAD51D (OMIM 602954), BRIP1 (OMIM 605882), and PALB2 mutations for preventing breast and ovarian cancer in the following ways. This evidence concerns the gene RAD51C and ovarian cancer.